Correction to: Oncogene https://doi.org/10.1038/s41388-021-02020-z, published online 23 September 2021
In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moskovich, D., Finkelshtein, Y., Alfandari, A. et al. Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene 42, 1508 (2023). https://doi.org/10.1038/s41388-023-02629-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-023-02629-2
